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Edited by Lukas HuberAbstract In this report, we show for the ﬁrst time that cera-
mide-1-phosphate (C1P) stimulates the phosphatidylinositol
3-kinase (PI3-K)/protein kinase B (PKB) pathway, which is a
major mechanism whereby growth factors promote cell survival.
Also, C1P induced IjB phosphorylation, and enhanced the DNA
binding activity of the transcription factor NF-jB. Apoptotic
macrophages showed a marked reduction of Bcl-XL levels, and
this was prevented by C1P. These ﬁndings suggest that C1P
blocks apoptosis, at least in part, by stimulating the PI3-K/
PKB/ NF-jB pathway and maintaining the production of antiap-
optotic Bcl-XL. Based on these and our previous observations, we
propose a working model for C1P in which inhibition of acid
sphingomyelinase and the subsequent decrease in ceramide levels
would allow cell signaling through stimulation of the PI3-K/PKB
pathway to promote cell survival.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ceramide-1-phosphate (C1P) is emerging as a new bioactive
molecule [1] capable of regulating vital pathophysiological
functions including cell proliferation [2,3], apoptosis [4],
phagocytosis [5], and inﬂammation [6,7]. Although the exis-
tence of C1P and its metabolizing enzymes, ceramide kinase
and C1P phosphatase, in mammalian tissues have been knownAbbreviations: A-SMase, acid sphingomyelinase; BMDM, bone mar-
row-derived macrophages; C1P, ceramide-1-phosphate; C2-, acetyl;
C8-, octanoyl; CAPE, caﬀeic acid phenylethyl ester; EMSA, electro-
mobility shift assay; FBS, fetal bovine serum; GAPDH, glyceralde-
hyde-3-phosphate dehydrogenase; M-CSF, macrophage colony
stimulating factor; MAPK, mitogen-activated protein kinase; ERK,
extracellular regulated kinase; MEK, MAPK/ERK kinase; MTS,
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium, inner salt]; PI, phosphatidylinositol;
PI3-K, phosphatidylinositol 3-kinase; PI (3,4,5) P3, phosphatidyl-
inositol (3,4,5) trisphosphate; PKB, protein kinase B; PLD, phos-
pholipase D; cPLA2, calcium-dependent cytosolic phospholipase
A2; PMS, phenazine methosulfate; PTX, pertussis toxin; S1P,
sphingosine-1-phosphate; TBS, Tris-buﬀered saline; TLC, thin-
layer chromatography
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doi:10.1016/j.febslet.2005.05.067for over a decade [8–10], current understanding of the meta-
bolic and signaling pathways that are aﬀected by this bioactive
sphingolipid is incomplete. We ﬁrst reported that synthetic
short-chain acetyl- (C2) and octanoyl (C8)-C1P [2], or natural
long-chain C1P [3] stimulated DNA synthesis and cell division
in rat or mouse ﬁbroblasts. These eﬀects were accompanied by
increases in the levels of proliferating cell nuclear antigen. Syn-
thetic C8-C1P was also able to stimulate the growth of chick
otic vesicle explants that were maintained in culture [11].
Nonetheless, unlike other mitogenic phospholipids such as
sphingosine-1-phosphate (S1P), lysophosphatidic acid, or
phosphatidic acid, in ﬁbroblasts C1P does not induce Ca2+
mobilization, does not aﬀect the activity of extracellular regu-
lated kinase 1-2 (ERK1-2) or phospholipase D (PLD), and
does not induce the expression of the early genes c-fos or
c-myc [2,3]. C1Ps also failed to induce Ca2+ mobilization in
neutrophils [12], and A549 cells [7]. However, C2-C1P has been
reported to induce Ca2+ mobilization in calf pulmonary artery
endothelial cells [13], thyroid FTRL-5 cells [14], and GH4C1
pituitary cells [15], and induction of ERK2 phosphorylation
has been observed in osteoblasts [16]. The reason for these dis-
crepancies is unknown at present, but it may be that the eﬀects
of C1P are cell type speciﬁc.
Two major ﬁndings regarding the biological actions of C1P
have recently been reported. First, we demonstrated that natu-
ral C1P blocks apoptosis of primary bone marrow-derived
macrophages (BMDM) incubated in the absence of growth fac-
tors. This action involved direct inhibition of acid sphingomy-
elinase (A-SMase) and blockade of the caspase-9/caspase-3
pathway [4]. Second, Pettus and co-workers [7] have shown that
C1P can stimulate calcium-dependent cytosolic phospholipase
A2 (cPLA2) thereby leading to arachidonic acid release and
generation of eicosanoids in lung carcinoma A549 cells. These
two reports are the ﬁrst to demonstrate that A-SMase and
cPLA2 are direct intracellular targets of C1P, and place C1P
as a central molecule in the regulation of apoptosis and inﬂam-
matory responses. A major mechanism whereby growth factors
promote cell survival is the activation of the phosphatidylinosi-
tol 3-kinase (PI3-K)/protein kinase B (PKB) (Akt) pathway
[17]. Activation of PI3-K leads to phosphatidylinositol (3,4,5)
trisphosphate (PI (3,4,5) P3) formation, and this results in the
recruitment of pleckstrin homology domain containing pro-
teins such as PKB. Recruitment of PKB to the cell membrane
results in its phosphorylation and activation, and this allows
it to phosphorylate downstream eﬀectors.blished by Elsevier B.V. All rights reserved.
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transcription factor NF-jB. The latter is an inducible heterodi-
meric factor responsible for the transcription of many impor-
tant antiapoptotic molecules including Bcl-XL. The p65
subunit of NF-jB is normally sequestered in the cytoplasm
by IjB; upon cell stimulation, IjK is activated causing phos-
phorylation of IjB at serines 32 and 36. Phosphorylated IjB
dissociates from p65 and is targeted for ubiquitination and
degradation by the 26S proteasome pathway. The p65 subunit
can then dimerize with p50, translocate to the nucleus, and
promote the transcription of NF-jB dependent target genes.
Activation of this pathway is suﬃcient to prevent death from
a variety of apoptotic stimuli including tumor necrosis factor,
UV, Trail, and Fas. Aberrant activation of this pathway is also
commonly seen in cancer cells [18].
We demonstrate here that C1P stimulates PI3-K activity
leading to PKB phosphorylation, activation of NF-jB, upreg-
ulation of Bcl-XL, and inhibition of apoptosis in BMDM.
These ﬁndings, together with our prior observations that
C1P inhibits A-SMase and the subsequent generation of cera-
mides and caspase 9/caspase 3 activation indicate that C1P is
an important regulator of cell survival.2. Materials and methods
2.1. Materials
RPMI 1640 medium, C1P (from bovine brain, containing predomi-
nantly stearic and nervonic acids), PI, PI (3,4,5) P3, phenazine metho-
sulfate (PMS), and ceramide were from Sigma/Aldrich Canada
(Oakville, ON). Deﬁned fetal bovine serum (FBS) was from Hyclone
(Logan, UT). Fisher Scientiﬁc (Edmonton, AB) supplied 3-(4,5-
dimethylthiazol-2-yl) 5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS). Antibody to the p85 subunit of PI3-K was
from Upstate Biotechnology, Inc. (Lake Placid, NY). [32P]orthophos-
phate was from ICN (Costa Mesa, CA). [c-32P]ATP (6000 Ci/mmol)
was from Dupont-NEN Research Products (Boston, MA). Antibodies
to ERK1-2, phospho-ERK1-2, phospho-IjK, PKB, phospho-PKB
(Ser 473), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were from Cell Signaling Technologies (Mississauga, ON), and anti-
bodies to Bcl-XL were supplied by BDPharmingen (Mississauga,
ON). Goat anti-rabbit IgG and goat anti-mouse IgG, horseradish per-
oxidase secondary anti-bodies, PD98059, UO126, LY294002, wort-
mannin, SC-514, and caﬀeic acid phenyl ethyl ester (CAPE) were
from Calbiochem supplied by VWR Canlab (Mississauga, ON).
2.2. Cell culture
BMDMs were isolated from femurs of 6- to 8-week-old female CD-1
mice as described [19]. Cells were plated in RPMI 1640 medium con-
taining 10% FBS and 10% L-cell conditioned medium as the source
of macrophage colony stimulating factor (M-CSF) [19]. After 24 h,
non-adherent cells were harvested and cultured in the above medium
until about 80% conﬂuence was reached (4–6 days) prior to use in
the experiments.
2.3. Cell viability assay
Macrophages were seeded at 25 000 cells/well in 96-well plates and
incubated overnight in RPMI 1640 with 10% FBS and 10% L-cell con-
ditioned medium as a source of M-CSF. The medium was then re-
placed by fresh RPMI 1640 medium in the presence or absence of
agonists and/or inhibitors as appropriate. Cell viability was estimated
by measuring the rate of reduction of the tetrazolium dye MTS as de-
scribed [19].
2.4. Detection and quantitation of intracellular PI (3,4,5) P3
Radioactivity in PI (3,4,5) P3 was determined essentially as de-
scribed [20] after labeling BMDM with 200 lCi/ml of [32P]ortho-
phosphate overnight in phosphate-free RPMI 1640 with 10% FBSand 10% L-cell conditioned medium as the source for M-CSF
[19]. Cells were then washed twice with RPMI 1640 without label
or M-CSF. The macrophages were stimulated with C1P for diﬀerent
times. Cells were then washed twice with ice-cold calcium-free phos-
phate buﬀered saline and scraped into 0.5 ml of methanol. They
were then washed with a further 0.5 ml of methanol, and the two
methanol samples were combined and mixed with 0.5 ml of chloro-
form. Lipids were extracted by separation of phases with a further
0.5 ml of chloroform and 0.9 ml of a solution containing 2 M
KCl and 0.2 M H3PO4. Chloroform phases were dried down under
N2 and lipids were separated by thin-layer chromatography (TLC)
using oxalate-treated silica Gel 60-coated glass plates. The plates
were developed to the top in chloroform/acetone/methanol/acetic
acid/water (80:30:26:24:14, by vol) [21], then dried and exposed to
autoradiography ﬁlm. The spot corresponding to 32P-labeled PI
(3,4,5) P3 in extracts was located by co-migration with a standard
produced by in vitro phosphorylation of PI (4,5) P2 by PI3-K
[20]. The PI (3,4,5) P3 spots were scraped from the TLC plate
and quantiﬁed by liquid scintillation counting. Values were normal-
ized to total 32P dpm in the extract.2.5. In vitro determination of PI3-K activity
The activity of PI3-K was determined in immunoprecipitates
essentially as described previously [22]. Brieﬂy, the cells were lysed
in solubilization buﬀer (50 mM Tris, pH 7.7, 1% Triton X-100,
10% glycerol, 100 mM NaCl, 2.5 mM EDTA, 10 mM NaF, 40 lg/
ml PMSF, 1 lM pepstatin, 15 lg/ml leupeptin, 0.2 lM NaVO4)
and 360 lg of whole cell lysate of each sample was incubated with
7.2 ll of anti-PI3-K p85 monoclonal antibody (Upstate Biotechnol-
ogy) overnight at 4 C. Samples were immunoprecipitated with
100 ll of Protein G Sepharose for 2 h at 4 C. The beads were
washed twice with solubilization buﬀer, three times with 10 mM
Tris, pH 7.4, in 0.1 mM NaVO4, and then twice with the assay dilu-
tion buﬀer (10 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA,
0.1 mM NaVO4). To each sample, 10 lg of PI as substrate, 5 ll
of 100 mM MgCl2, 4 mM ATP, and 10 lCi of [c-
32P]ATP were
added and then incubated at 37 C for 15 min. Reactions were
stopped with 100 ll of 1 M HCl and then 200 ll of chloroform/
methanol (1:1, v/v). Phases were separated and the lower phase
was retained for lipid analysis. Lipids were separated by TLC in
oxalate-treated silica gel 60 plates that were run in chloroform/meth-
anol/water/28% NaOH (90:70:15:5, by vol). The plates were stained
with iodine and the PI3-P spots were scraped from the TLC plate
and quantitated by liquid scintillation counting.2.6. Nuclear preparations and electromobility shift assay
Cells were grown in 100 mm tissue culture plates. Isolation of nu-
clei and radioactive labeling of electromobility shift assay (EMSA)
NF-jB probe was performed as previously described [23]. Nuclear
extracts (10 lg) were preincubated for 15 min in binding buﬀer
(20 mM HEPES, pH 7–9, 100 mM KCl, 10% glycerol, 1 mM dithi-
othreitol) containing 1 lg of poly(dIdC) (Amersham). The probe
(20 000 counts/min) was then added and the reaction mixture incu-
bated at room temperature for 30 min before electrophoresis on a
5% non-denaturing polyacrylamide gel in 0.25· TBE Tris 89 mM,
boric acid 89 mM, EDTA 2 mM (TBE) at 200 V for 1.5 h. The
gel was subsequently dried for 45 min and imaged using a Bio-
Rad FX phosphor-imager.2.7. Western blotting
Macrophages were harvested and lysed in ice-cold homogenization
buﬀer as described [19]. Aliquots of protein (40–50 lg) from each
sample were loaded and separated by SDS–PAGE, using 10% or
15% separating gels. Proteins were transferred onto nitrocellulose
paper and blocked for 1 h with 4% skim milk in Tris-buﬀered saline
(TBS) containing 0.01% NaN3 and 0.1% Tween 20, and then incu-
bated overnight with the primary antibody in TBS/0.1% Tween 20
at room temperature. After three washes with TBS/0.1% Tween
20, membranes were incubated with horseradish peroxidase-conju-
gated secondary antibody at 1:5000 dilution for 1 h. Bands were
visualized using enhanced chemiluminescence, and recorded with a
Fluorochem 8000 imaging system (Canberra Packard Canada, Miss-
issauga, ON).
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Results are expressed as means ± S.E.M. of three independent exper-
iments performed in triplicate or quadruplicate, unless indicated other-
wise. Statistical analysis was done using Students t test with the level
of signiﬁcance set at P < 0.05.Fig. 1. Ceramide-1-phosphate stimulates PI3-K activity. Upper panel:
BMDMwere treated as indicated in Section 2, and incubated with C1P
(30 lM) at various times, as indicated. Whole cell lysates were
subjected to immunoprecipitation with anti-PI3-K p85 monoclonal
antibody. PI3-K activity was assayed in the immunoprecipitates using
PI as the substrate. 32P-labeled PI-3-P from TLC plates was excised
and quantitated in scintillation counter. Results are expressed as the
fold stimulation relative to incubations in the absence of C1P, and they
are the means ± S.E.M. of three independent experiments. Lower
panel: 32P-labeled BMDM were stimulated for various times with C1P
(30 lM). PI (3,4,5) P3 in BMDM was located using an authentic
standard that was synthesized enzymatically [20]. The PI (3,4,5) P3
spot was excised and 32P quantitated by scintillation counting. The
results were calculated as a percentage of the radioactivity present in
32P-PI (3,4,5) P3 compared to that in total 32P-labeled lipids. Results
are the mean of two independent experiments. The values for each
independent time point were: 0.022/0.024, 0.029/0.037, 0.042/.052,
0.038/0.048, 0.040/0.050, for 0, 5, 10, 15, and 20 min of incubation with
C1P, respectively.3. Results
3.1. C1P stimulates the PI3-K/PKB pathway
We and others have previously shown that BMDM under-
go apoptosis when they are incubated in the absence of
M-CSF [4,19,24,25]. We have also reported that M-CSF
withdrawal causes stimulation of A-SMase activity in
BMDM, and have suggested that this is one of the mecha-
nisms whereby these cells become apoptotic [4,19,25]. In
addition, we recently found that C1P blocks apoptosis in
BMDM at least in part through a mechanism involving inhi-
bition of A-SMase and, as a consequence, a decrease of cer-
amide levels [4]. However, phosphatidic acid (PA), which is
a glycerolipid analogue of C1P [2], and lyso-PA failed to in-
hibit apoptosis in these cells ([25], and data not shown). The
present studies were done to determine whether the antiapo-
ptotic eﬀect of C1P also involves stimulation of the PI3-K/
PKB pathway, which plays a central role in the regulation
of cell survival and proliferation. To test for PI3-K activa-
tion, BMDM were incubated for varying times with C1P
and then PI3-K activity was immunoprecipitated from whole
cell lysates, and assayed in vitro using 32P-labeled PI. As
shown in Fig. 1(upper panel), C1P stimulated the formation
of 32P-PI (3) P in a time-dependent manner. The activity of
PI3-K was also determined using an in vivo approach, by
measuring the formation of PI (3,4,5) P3, in live cells that
were pre-labeled overnight with 32P orthophosphate. Fig. 1
(lower panel) shows that C1P increased the formation of
PI (3,4,5) P3 in intact cells. In these experiments, an aque-
ous dispersion of C1P was prepared by sonication, and the
optimal concentration of C1P was 30 lM. When C1P is dis-
solved in a mixture of 49:1 methanol/dodecane or ethanol/
dodecane, dispersion is improved and eﬀects on cell prolifer-
ation in ﬁbroblasts or arachidonic acid release in A549 cells
have been reported at concentrations as low as 2.5 lM
[3,6,7]. In the present work, we found that although
2.5 lM C1P was eﬀective in promoting macrophage survival
when added in methanol/dodecane, the solvent mixture
alone caused an increase of about 18% on macrophage sur-
vival, and therefore it was decided not to use methanol/
dodecane in subsequent experiments.
A downstream target of PI3-K that is involved in promoting
cell survival is PKB. We have previously demonstrated that
stimulation of PKB is critical for macrophage survival
[19,25], and this is also the case for many other cell types
[26]. Therefore, we tested to see whether PI3-K activation by
C1P could lead to phosphorylation of PKB. Immunoblot anal-
ysis using a speciﬁc antibody against the Ser 473 phosphoryla-
tion site of PKB demonstrated that C1P was able to induce
rapid phosphorylation of this kinase (Fig. 2), and this occurred
within the same time frame of PI3-K activation and PI (3,4,5)
P3 formation (Fig. 1). The mitogen-activated protein kinases
(MAPKs), ERK1-2 have also been reported to play a central
role in cell survival [27–29]. In particular, ERK2 has been
shown to be phosphorylated by stimulation of osteoblasticcells with short-chain C8-C1P [16]. However, we found that
C1P failed to induce phosphorylation of ERK1-2 in BMDM
(not shown), which is in agreement with our previous work
in rat or mouse ﬁbroblasts [2,3].
3.2. Involvement of the PI3-K/PKB pathway in the antiapoptotic
eﬀect of C1P
To evaluate whether the PI3-K pathway was involved in the
inhibition of apoptosis by C1P, we tested the eﬀects of selective
inhibitors on cell survival in the presence of C1P. As shown in
Fig. 3(upper panel), the PI3-K inhibitors LY294002 (5 lM)
and wortmannin (100 nM) blocked the eﬀect of C1P on
macrophage survival, whereas the MAPK/ERK kinase
(MEK) inhibitors PD98059 (10 lM) and UO126 (2 lM) did
not, even though both of these inhibitors blocked ERK1/
Fig. 3. Eﬀect of MAPK inhibitors, PI3-K inhibitors, and PTX on
C1P-mediated macrophage survival. BMDM were seeded at 25 · 103
cells/well in 96-well plates. They were then preincubated with vehicle,
or with the MEK inhibitors PD98059 (PD) at 10 lM and UO126 (UO)
at 2 lM, or with the PI3-K inhibitors LY294002 (LY) at 5 lM and
wortmannin (W) at 100 nM for 1 h before treatment with 30 lM C1P,
as indicated (wortmannin was added back to the cells at 5 and 10 h
after stimulation with C1P so as to compensate for its relatively rapid
degradation in tissue culture medium) (upper panel). Cells were
preincubated for 18 h with vehicle, or with 100 ng/ml PTX before
treatment with C1P, as indicated (lower panel). CTRL indicates
conditions in the absence of agonist or inhibitors. Macrophage
viability was measured after 30 h by the MTS assay. Results are
expressed relative to control cells at 0 h and are means ± SEM of three
independent experiments performed in quadruplicate.
Fig. 2. Ceramide-1-phosphate induces PKB phosphorylation. BMDM
were seeded at 5 · 106 cells/100 mm dish and preincubated in RPMI
1640 without M-CSF and serum for 4 h. C1P (30 lM) was then added
to the cells for various times, as indicated. Phosphorylation of PKB
was examined by immunoblotting as described in Section 2 with
antibodies speciﬁc to PKB phospho-Ser 473 and total PKB. Similar
results were obtained in each of two replicate experiments. PKB, total
protein kinase B protein; P-PKB, phospho-PKB protein.
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fect of C1P was unaﬀected by pretreatment of the macro-
phages with pertussis toxin (PTX) (100 ng/ml) (Fig. 3, lower
panel). Higher PTX concentrations (up to 1 lg/ml also failed
to inhibit the prosurvival eﬀect of C1P. However, these PTX
concentrations were not used in further experiments because
they increase cell viability by an unknown mechanism. In addi-
tion, C1P-induced PKB phosphorylation was also unaltered in
the presence of PTX (not shown). Taken together these obser-
vations suggest that the PI3-K/PKB signaling cascade, but not
the MAPK (ERK) pathway, is involved in C1P-stimulated
macrophage survival, and that the eﬀect of C1P is independent
of interaction with Gi/o coupled receptors.
3.3. The prosurvival eﬀect of C1P requires the activation of
IjB/NF-jB, and the expression of Bcl-XL
An important target of PKB is the NF-jB transcription fac-
tor. Therefore, we next tested the ability of C1P to activate this
pathway. The activation of NF-jB requires the phosphoryla-
tion of IjB by IjK, so we examined the phosphorylation status
of IjB in C1P-treated cells using immunoblot analysis. C1P
was able to stimulate the phosphorylation of IjB in a time-
dependent fashion (Fig. 4A). To complement this, we exam-
ined the ability of C1P to induce DNA binding of activated
NF-jB, using nuclear extracts and EMSA. Fig. 4B shows that
there is minimal basal binding of NF-jB to DNA in apoptotic
macrophages. Of interest, NF-jB binding to DNA was signif-
icantly increased on exposure of the cells to C1P. This eﬀect of
C1P was as robust as the lipopolysaccharide (LPS)-induced
NF-jB response, indicating that C1P is a potent activator of
NF-jB in murine macrophages.
There is convincing evidence that the PI3-K/PKB signaling
cascade can aﬀect Bcl-2 family members, such as Bcl-XL. We
recently reported that M-CSF withdrawal caused a selective
decrease in the level of antiapoptotic Bcl-XL protein [19]. Also,
it is known that Bcl-XL expression is dependent upon NF-jB
activation, and that this is a requirement for the antiapoptotic
eﬀect of oxidized LDL [19]. Since we observed a strong activa-
tion of NF-jB by C1P, we next tested whether its downstream
target Bcl-XL would also be upregulated. Upon examination
of Bcl-XL by Western blotting, we found that it was downreg-
ulated in apoptotic BMDM after 30 h of incubation in the ab-
sence of M-CSF, and that C1P completely restored Bcl-XL
expression in these cells (Fig. 4C). This observation is consis-
tent with the antiapoptotic eﬀect of C1P. Taken together, these
ﬁndings demonstrate for the ﬁrst time that C1P is able to reg-
ulate the NF-jB pathway, and the subsequent expression of
antiapoptotic Bcl-XL.3.4. Involvement of NF-jB in the antiapoptotic eﬀect of C1P
To evaluate whether NF-jB was required for the inhibition
of apoptosis by C1P, we tested the eﬀects of selective inhibitors
on cell survival in the presence of C1P. As shown in Fig. 5, the
NF-jB inhibitors CAPE and SC-514 blocked the prosurvival
eﬀect of C1P in the macrophages, suggesting that NF-jB is re-
quired for this action of C1P.3.5. Working model of the mechanism whereby C1P promotes
cell survival
Based on the ﬁndings presented in this study and our re-
cently published work [4], the working model that we propose
Fig. 5. NF-jB inhibitors block C1P-mediated macrophage survival.
BMDM were seeded at 25 · 103 cells/well in 96-well plates. They were
then preincubated with vehicle, or with the NF-jB inhibitors CAPE
(12.5 lg/ml) or SC-514 (50 lM) for 1 h before treatment with 30 lM
C1P, as indicated. CTRL indicates conditions in the absence of agonist
or inhibitors. Macrophage viability was measured after 30 h by the
MTS assay. Results are expressed relative to control cells at 0 h and
are means ± SEM of three independent experiments performed in
quadruplicate.
Fig. 6. Working model for the induction of cell survival by C1P. C1P
prevents macrophage apoptosis by at least two primary mechanisms:
(1) by inhibiting A-SMase and the subsequent generation of ceramide
and caspase 9/ caspase 3 activation and (2) by activating the PI3-K/
Fig. 4. Ceramide-1-phosphate induces IjB phosphorylation, NF-jB
activation and Bcl- XL expression. Panel A: BMDM were seeded and
incubated as in Fig. 3. C1P (30 lM) was added to the cells for various
times, as indicated Phosphorylation of IjB was examined by immu-
noblotting as described in Section 2. Similar results were obtained in
each of two replicate experiments. Panel B: BMDM were seeded and
incubated as in Fig. 3. Nuclear NF-jB DNA binding activity was
determine by EMSA, after stimulation of the cells at various times with
C1P (C) (30 lM) or LPS (L) (200 ng/ml), as described in Section 2.
Similar results were obtained in each of two replicate experiments.
Panel C: BMDM were seeded and treated as in Fig. 4. Bcl-XL and
GAPDH levels were examined by immunoblotting as described in
Section 2. Similar results were obtained in each of three replicate
experiments. CTR 0 h, control at 0 h; 30 h, time of incubation in the
absence of M-CSF.
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vival is outlined in Fig. 6. This suggests that C1P prevents mac-
rophage apoptosis by stimulating the PI3-K/PKB pathway,
and by inhibiting A-SMase activation and the subsequent gen-
eration of ceramide. Ceramide is known to inhibit PKB activ-
ity and therefore inhibition of its formation would facilitate
signal transduction through the PI3- K/PKB pathway to
promote cell survival.PKB (Akt) pathway. PKB-mediated phosphorylation of IjB leads to
activation of NF-jB, which then maintains expression of Bcl-XL
thereby promoting cell survival.4. Discussion
In previous studies, we have shown that apoptosis of
BMDM induced by M-CSF withdrawal involves stimulation
of A-SMase and ceramide accumulation [19,25]. A-SMase acti-
vation seems to be essential for apoptosis in the macrophages
because BMDM that were obtained from A-SMase knockout
mice (generously provided by Dr. Richard N. Kolesnick) were
resistant to apoptosis upon M-CSF withdrawal (A. Go´mez-
Mun˜oz, unpublished work). In addition, desipramine, a sphin-
gomyelinase inhibitor, prevented ceramide accumulation andblocked cell death [19], whereas incubation of the macrophages
with the cell-permeable C2-ceramide rendered the cells apopto-
tic [25].
In a more recent study, we have demonstrated that natural
C1P blocks apoptosis in primary BMDM. The mechanism
whereby C1P exerts this action probably involves direct inhibi-
tion of A-SMase, as C1P was able to completely inhibit this en-
zyme activity in cell homogenates [4]. In addition, C1P
inhibited DNA fragmentation, the stimulation of caspases 3
A. Go´mez-Mun˜oz et al. / FEBS Letters 579 (2005) 3744–3750 3749and 9, and PARP cleavage [4]. Incubation of BMDM with S1P
in the absence of M-CSF also led to inhibition of A-SMase,
but unlike C1P, S1P did not inhibit A-SMase directly [25].
The physiological relevance of the prosurvival eﬀect of C1P
is emphasized by our ﬁnding that the intracellular levels of
C1P are decreased in apoptotic macrophages [4]. The mecha-
nism for the depletion of C1P levels in apoptotic cells has
not been completely deﬁned but it may be explained, at least
in part, by a 30% increase in the activity of C1P phosphatase
that we have observed in apoptotic BMDM (unpublished
observation).
The main ﬁnding of the present studies is that C1P stimu-
lates the PI3-K/PKB pathway, which is a major mechanism
by which growth factors promote cell survival. The eﬀects of
C1P on inhibition of A-SMase and activation of PI3-K are
consistent with previous observations by Testai et al. [31]
who have recently demonstrated that inhibition of PI3-K leads
to A-SMase activation in oligodendrocytes.
The importance of the PI3-K/PKB pathway in C1P-induced
cell survival was demonstrated using the two selective PI3-K
inhibitors, LY294002 and wortmannin in the presence of
C1P. Both of these inhibitors completely abolished the antiap-
optotic eﬀect of C1P, suggesting that the PI3-K/PKB pathway
is involved in the prosurvival eﬀect of C1P. However, C1P
does not aﬀect the phosphorylation state of ERK1-2 in the
macrophages, and therefore the MAPK pathway does not
seem to be essential for the prosurvival eﬀect of C1P.
Another important observation in this work was that C1P
induced activation of the PKB downstream target NF-jB, sup-
porting our previous ﬁnding that PI3-K is an important regu-
lator of NF-jB activation in BMDM [19]. As expected from
these results, C1P enhanced the ability of NF-jB to bind to
DNA, suggesting that activation of this transcription factor
is an important component of the signaling pathway leading
to inhibition of apoptosis by C1P. In the present work, we also
show that C1P upregulates antiapoptotic Bcl-XL, which is a
downstream target of NF-jB. This parallels the eﬀect of oxi-
dized LDL in BMDM, which also causes upregulation of
Bcl-XL via activation of PI3-K/PKB and inhibition of A-
SMase [19]. Inhibition of NF-jB activation by the selective
inhibitors CAPE, or SC-514 abolished the antiapoptotic eﬀect
of C1P suggesting that this transcription factor was required
for C1P-mediated survival in the macrophages. The above re-
sults provide the ﬁrst evidence for a novel biological role of
C1P in the regulation of cell survival by the PI3-K/PKB/NF-
jB pathway. Furthermore, the development of drugs that inhi-
bit C1P formation or that stimulate its degradation may have
potential applications in inﬂammatory diseases, as well as can-
cer, in which NF-jB is upregulated.
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